On March 10, 2023, the Board of Directors of Histogen Inc. approved removing the interim title of Steven J. Mento, Ph.D. In connection with Dr. Mento now serving as Chief Executive Officer of the Company, Company entered into an amendment and restatement of his executive employment agreement pursuant to which he is entitled to twelve (12) months' severance, including target bonus, and reimbursement of COBRA premium reimbursement in the event of a termination without cause or termination by Good Reason (as defined in the CEO Agreement), which such severance and COBRA reimbursement is increased to eighteen (18) months in the event of a termination after a change of control event. The CEO Agreement also provides for accelerated vesting of certain of his outstanding options in the event of termination in connection with a change in control.